Physician profile
William M Farmer
NPI 1558374850
$12,252.25
in general payments reported to CMS, 2019-2025
39 companies · $2,054 in 2025
The $2,054 reported for 2025 was more than what 80% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,810 · 2020: $850 · 2021: $1,831 · 2022: $1,852 · 2023: $1,792 · 2024: $2,063 · 2025: $2,054.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,834 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,834.39 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,178.91 | 2019-2025 | |
| Pfizer INC. | $1,117.80 | 2019-2025 | |
| Janssen Biotech, INC. | $963.26 | 2019-2025 | Stelara, Tremfya |
| Qol Medical, LLC | $762.20 | 2019-2025 | Sucraid, Sucraid |
| Celgene Corporation | $696.63 | 2021-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $654.45 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $529.41 | 2019-2025 | Entyvio, Gattex |
| Intercept Pharmaceuticals, INC. | $497.63 | 2019-2025 | Ocaliva |
| Merck Sharp & Dohme LLC | $371.36 | 2019-2024 | Dificid |
| Nestle Healthcare Nutrition INC. | $343.98 | 2021-2023 | |
| Ardelyx, INC. | $265.71 | 2023-2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $240.59 | 2024-2025 | Zenpep |
| Gilead Sciences, INC. | $219.95 | 2019-2025 | Epclusa |
| Madrigal Pharmaceuticals | $152.36 | 2024-2025 | Rezdiffra, Resmetirom |
| Ironwood Pharmaceuticals, INC | $145.40 | 2019-2023 | Linzess |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $137.56 | 2023-2025 | Dupixent |
| Allergan, INC. | $127.11 | 2019 | |
| Janssen Scientific Affairs, LLC | $87.04 | 2019 | |
| Genzyme Corporation | $80.41 | 2022-2024 | |
| Ferring Pharmaceuticals INC. | $80.39 | 2020-2025 | Clenpiq, Cimzia, Rebyota |
| Braintree Laboratories, INC. | $76.76 | 2019-2025 | Sutab, Suflave |
| Evoke Pharma, INC. | $69.69 | 2020-2024 | |
| Alnylam Pharmaceuticals INC. | $57.11 | 2021 | |
| Phathom Pharmaceuticals, INC. | $53.34 | 2023-2024 | Voquezna |
| Lilly USA, LLC | $48.39 | 2024-2025 | Omvoh |
| Stryker Corporation | $39.11 | 2024 | Fluid Management System |
| Boston Scientific Corporation | $36.85 | 2025 | Compliance Endokit, Resolution 360 Ultra Clip |
| Amgen INC. | $35.42 | 2021 | |
| Axonics, INC. | $33.75 | 2021-2024 | Axonics |
| Bausch & Lomb Americas INC. | $24.63 | 2025 | Xiidra, Miebo |
| Endogastric Solutions, INC | $24.53 | 2023 | Esophyx |
| Fresenius Kabi USA, LLC | $17.52 | 2023 | Idacio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.09 | 2023 | Cyltezo |
| Sun Pharmaceutical Industries INC. | $14.18 | 2025 | |
| Celltrion USA INC. | $14.13 | 2025 | Vegzelma |
| Alfasigma USA, INC. | $14.02 | 2020 | |
| Redhill Biopharma INC. | $13.30 | 2020 | |
| Ucb, INC. | $11.28 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$9,605.77 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Farmer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.